Title : Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells.

Pub. Date : 2019 Feb

PMID : 30483795






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR-mutant Ba/F3 cells. osimertinib epidermal growth factor receptor Homo sapiens
2 Afatinib, a second-generation EGFR-TKI and osimertinib, a third-generation EGFR-TKI, are both standard therapies for patients with these types of cancer. osimertinib epidermal growth factor receptor Homo sapiens